Blu-5937
- Generic Name
- Blu-5937
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 21
- Registration Number
- NCT06222892
- Locations
- 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States
Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects
- First Posted Date
- 2023-12-22
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 34
- Registration Number
- NCT06179537
- Locations
- 🇬🇧
Richmond Pharmacology Ltd., London, United Kingdom
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
- Conditions
- CoughHealthy
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 45
- Registration Number
- NCT05959447
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 42
- Registration Number
- NCT05899829
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 825
- Registration Number
- NCT05599191
- Locations
- 🇺🇸
Remington-Davis, Inc., Columbus, Ohio, United States
🇺🇸Well Pharma Medical Research Corporation, Miami, Florida, United States
🇿🇦Dr JM Engelbrecht Trial Site, Somerset West, Western Cape, South Africa
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 825
- Registration Number
- NCT05600777
- Locations
- 🇮🇳
Government Hospital for Chest and Communicable Diseases, Visakhapatnam, Andhra Pradesh, India
🇺🇸In-Quest Medical Research, LLC, Norcross, Georgia, United States
🇺🇸Geisinger Medical Center, Danville, Pennsylvania, United States
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 142
- Registration Number
- NCT04693195
- Locations
- 🇺🇸
Bellus Health Investigational Site #29, Norman, Oklahoma, United States
🇺🇸Bellus Health Investigational Site #25, Seattle, Washington, United States
🇺🇸Bellus Health Investigational Site #15, Hialeah, Florida, United States
Evaluation of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 310
- Registration Number
- NCT04678206
- Locations
- 🇺🇸
Montana Medical Research, Missoula, Montana, United States
🇨🇦Diex Recherche - Québec, Québec, Quebec, Canada
🇨🇦Inspiration Research Limited, Toronto, Quebec, Canada
A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 68
- Registration Number
- NCT03979638
- Locations
- 🇺🇸
Allergy Asthma & Sinus Center, Greenfield, Wisconsin, United States
🇺🇸Clinical Research of Gastonia, Gastonia, North Carolina, United States
🇬🇧Prince Phillip Hospital, Llanelli, United Kingdom
BLU-5937: First-in-Human, Single and Multiple Doses Escalation, Safety, Tolerability, Pharmacokinetics and Food Effect
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 90
- Registration Number
- NCT03638180
- Locations
- 🇨🇦
Alta Sciences Algorithme Pharma, Mount-Royal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.